Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for Ikena Oncology in a research report issued to clients and investors on Thursday, May 8th. William Blair analyst M. Phipps forecasts that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Ikena Oncology's current full-year earnings is ($0.91) per share. William Blair also issued estimates for Ikena Oncology's Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.19) EPS.
Ikena Oncology Price Performance
Shares of NASDAQ:IKNA opened at $1.14 on Monday. The business's fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.46. Ikena Oncology has a fifty-two week low of $0.97 and a fifty-two week high of $1.94. The stock has a market capitalization of $54.77 million, a price-to-earnings ratio of -0.92 and a beta of 0.47.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03.
Institutional Trading of Ikena Oncology
A number of large investors have recently bought and sold shares of the stock. XTX Topco Ltd grew its position in Ikena Oncology by 350.6% in the first quarter. XTX Topco Ltd now owns 56,452 shares of the company's stock valued at $72,000 after acquiring an additional 43,924 shares during the period. BML Capital Management LLC grew its position in Ikena Oncology by 3.5% in the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company's stock valued at $4,750,000 after acquiring an additional 124,937 shares during the period. Squarepoint Ops LLC acquired a new position in Ikena Oncology in the fourth quarter worth $72,000. BNP Paribas Financial Markets acquired a new position in Ikena Oncology in the fourth quarter worth $72,000. Finally, Northern Trust Corp boosted its stake in Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after purchasing an additional 9,456 shares in the last quarter. 75.00% of the stock is currently owned by institutional investors.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
